Summary of Purpose
The primary objective is to evaluate the safety and tolerability of single ascending dose of Y-2 sublingual tablets in healthy male and female adult subjects. The secondary objective is to characterize the single-dose pharmacokinetics of Y-2 sublingual tablets in healthy male and female adult subjects.Read More →
The following dates are available for this trial. Trial information last updated on 4 April 2018.
|1 Apr 2018||21 Mar 2018||1 Aug 2018||1 Oct 2018||1 Apr 2018||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- David Z. Wang, M.D.
email@example.com (309) 624-9500